Inventor · disambiguated record
Geoffrey T. Yarranton
Also filed as: YARRANTON GEOFFREY · YARRANTON GEOFFREY T · YARRANTON GEOFFREY THOMAS
36 granted patents·19 pending applications·1,013 citations·filing 1988–2017
98Inventor score
Files withKALOBIOS PHARMACEUTICALS INC17MEDAREX INC9BEBBINGTON CHRISTOPHER R7ALUSUISSE HOLDINGS AG4YARRANTON GEOFFREY T4
Top patents by PatentIndex Score
55 records- 0198US7129261B2Cytotoxic agentsMEDAREX INC·Filed 2002·Granted Oct 31, 2006·282 cites·24 claims
- 0294US7329507B2Prodrug compounds with isoleucineMEDAREX INC·Filed 2006·Granted Feb 12, 2008·27 cites·5 claims
- 0394US7115573B2Prodrug compounds with an isoleucineMEDAREX INC·Filed 2001·Granted Oct 3, 2006·61 cites·41 claims
- 0493US7981843B2Antibody specificity transfer using minimal essential binding determinantsKALOBIOS PHARMACEUTICALS INC·Filed 2005·Granted Jul 19, 2011·36 cites·14 claims
- 0593US7214663B2Tripeptide prodrug compoundsMEDAREX INC·Filed 2001·Granted May 8, 2007·52 cites·26 claims
- 0693US6653101B1Recombinant DNA method and host cellsLONZA AG·Filed 2000·Granted Nov 25, 2003·40 cites·13 claims
- 0792US5864019AMultivalent antigen-binding proteinsCELLTECH LTD·Filed 1995·Granted Jan 26, 1999·136 cites·21 claims
- 0891US7425541B2Enzyme-cleavable prodrug compoundsMEDAREX INC·Filed 2001·Granted Sep 16, 2008·37 cites·23 claims
- 0990US8034787B2Enzyme-cleavable prodrug compoundsMEDAREX INC·Filed 2008·Granted Oct 11, 2011·8 cites·17 claims
- 1089US8075885B2Methods of treating heart failure using an anti-GM-CSF antibodyBEBBINGTON CHRISTOPHER R·Filed 2009·Granted Dec 13, 2011·6 cites·28 claims
- 1189US7816317B2Tripeptide prodrug compoundsMEDAREX INC·Filed 2007·Granted Oct 19, 2010·13 cites·26 claims
- 1288US8398972B2Methods of treating dementia using a GM-CSF antagonistBEBBINGTON CHRISTOPHER R·Filed 2010·Granted Mar 19, 2013·9 cites·30 claims
- 1387US7696313B2Prodrug compounds with isoleucineMEDAREX INC·Filed 2008·Granted Apr 13, 2010·7 cites·10 claims
- 1486US5891693ARecombinant DNA methods vectors and host cellsALUSUISSE HOLDINGS AG·Filed 1995·Granted Apr 6, 1999·77 cites·25 claims
- 1582US8168183B2Antibodies to granulocyte-macrophage colony-stimulating factorBEBBINGTON CHRISTOPHER R·Filed 2009·Granted May 1, 2012·4 cites·36 claims
- 1681US5879936ARecombinant DNA methods, vectors and host cellsALUSUISSE HOLDINGS AG·Filed 1992·Granted Mar 9, 1999·65 cites·9 claims
- 1780US8664365B2Antibodies to EphA3LUEHRSEN KENNETH·Filed 2010·Granted Mar 4, 2014·6 cites·29 claims
- 1879US9017674B2Antibodies to granulocyte-macrophage colony-stimulating factorBEBBINGTON CHRISTOPHER R·Filed 2012·Granted Apr 28, 2015·3 cites·4 claims
- 1979US8828393B2Methods for the therapy of inflammatory bowel disease using a type-1 interferon antagonistPICKFORD LESLEY B·Filed 2011·Granted Sep 9, 2014·6 cites·16 claims
- 2078US8642039B2Method of treating a staphylococcus infection in a patient having a low-level pathogenic Pseudomonas aeruginosa infectionYARRANTON GEOFFREY T·Filed 2010·Granted Feb 4, 2014·4 cites·26 claims
- 2178US8211648B2Secretion of antibodies without signal peptides from bacteriaYARRANTON GEOFFREY T·Filed 2005·Granted Jul 3, 2012·2 cites·16 claims
- 2278US7939076B2Methods for the therapy of Inflammatory Bowel Disease using a type-1 interferon antagonistMEDAREX INC·Filed 2004·Granted May 10, 2011·9 cites·16 claims
- 2376US5965405AMethod for producing Fv fragments in eukaryotic cellsCELLTECH LTD·Filed 1993·Granted Oct 12, 1999·34 cites·10 claims
- 2473US5015573ADNA vectors and their use in recombinant DNA technologyCELLTECH LTD·Filed 1988·Granted May 14, 1991·51 cites·18 claims
- 2571US9109032B2Methods of treating hematological proliferative disorders by targeting EphA3 expressed on aberrant vasculature in bone marrowYARRANTON GEOFFREY T·Filed 2012·Granted Aug 18, 2015·1 cites·14 claims
- 2671US5747308ARecombinant DNA methodALUSUISSE HOLDINGS AG·Filed 1995·Granted May 5, 1998·27 cites·13 claims
- 2768US10080792B2Influenza vaccine and therapyENGEN BIO INC·Filed 2016·Granted Sep 25, 2018·1 cites·3 claims
- 2867US2015030614A1Antibodies to the pcrv antigen of pseudomonas aeruginosaKALOBIOS PHARMACEUTICALS INC·Filed 2014·Application pending·0 cites
- 2965US8044181B2Antibodies to the PcrV antigen of Pseudomonas aeruginosaKALOBIOS PHARMACEUTICALS INC·Filed 2008·Granted Oct 25, 2011·0 cites·15 claims
- 3060US2014370010A1Treatment of leukemias and chronic myeloproliferative diseases with antibodies to epha3KALOBIOS PHARMACEUTICALS INC·Filed 2014·Application pending·0 cites
- 3159US2009181020A1Methods of Treating Bone-Loss Disorders Using a GM-CSF AntagonistKALOBIOS PHARMACEUTICALS INC·Filed 2009·Application pending·0 cites
- 3258US8877191B2Antibodies to the PcrV antigen of Pseudomonas aeruginosaBEBBINGTON CHRISTOPHER R·Filed 2011·Granted Nov 4, 2014·0 cites·18 claims
- 3356US9290571B2Antibodies to EphA3KALOBIOS PHARMACEUTICALS INC·Filed 2013·Granted Mar 22, 2016·0 cites·20 claims
- 3456US9127046B2Secretion of antibodies without signal peptides from bacteriaYARRANTON GEOFFREY T·Filed 2012·Granted Sep 8, 2015·0 cites·7 claims
- 3556US2008206241A1Methods of Treating Chronic Inflammatory Diseases Using a GM-CSF AntagonistKALOBIOS PHARMACEUTICALS INC·Filed 2007·Application pending·0 cites
- 3654US8637016B2EphA3 antibodies for the treatment of solid tumorsLACKMANN MARTIN·Filed 2008·Granted Jan 28, 2014·0 cites·30 claims
- 3754US5866359ATransactivation method of regulating foreign gene expressionALUSUISSE HOLDINGS AG·Filed 1995·Granted Feb 2, 1999·9 cites·12 claims
- 3854US2017226227A1Treatment of Leukemias and Chronic Myeloproliferative Diseases with Antibodies to EphA3KALOBIOS PHARMACEUTICALS INC·Filed 2016·Application pending·0 cites
- 3953US8834870B2Treatment of leukemias and chronic myeloproliferative diseases with antibodies to EphA3BEBBINGTON CHRISTOPHER R·Filed 2010·Granted Sep 16, 2014·0 cites·30 claims
- 4051US2013156759A1Methods of treating dementia using a gm-csf antagonistKALOBIOS PHARMACEUTICALS INC·Filed 2013·Application pending·0 cites
- 4151US2015329647A1Methods of Treating Hematological Proliferative Disorders by Targeting EphA3 Expressed on Aberrant Vasculature in Bone MarrowKALOBIOS PHARMACEUTICALS INC·Filed 2015·Application pending·0 cites
- 4250US10919983B2Immunoglobulin variable region cassette exchangeHUMANIGEN INC·Filed 2015·Granted Feb 16, 2021·0 cites·19 claims
- 4350US2012009191A1Methods of treating bone-loss disorders using a gm-csf antagonistBEBBINGTON CHRISTOPHER R·Filed 2011·Application pending·0 cites
- 4449US2008171038A1Methods of treating idiopathic thrombocytopenia purpura using a gm-csf antagonistKALOBIOS PHARMACEUTICALS INC·Filed 2007·Application pending·0 cites
- 4547US2006134098A1Immunoglobulin variable region cassette exchangeKALOBIOS INC·Filed 2005·Application pending·0 cites
- 4646US2015344565A1Antibodies to granulocyte-macrophage colony-stimulating factorKALOBIOS PHARMACEUTICALS INC·Filed 2015·Application pending·0 cites
- 4744US2017335001A1Detection of EphA3 as a Marker of the Presence of a Solid TumorKALOBIOS PHARMACEUTICALS INC·Filed 2016·Application pending·0 cites
- 4843US9045539B2Anti-EMR1 antibodiesLUEHRSEN KENNETH·Filed 2012·Granted Jun 2, 2015·0 cites·10 claims
- 4943US2013109586A1Generation of antibodies to an epitope of interest that contains a phosphomimetic amino acidKALOBIOS PHARMACEUTICALS INC·Filed 2012·Application pending·0 cites
- 5042US2019270821A1Epha3 antibodies for the treatment of pulmonary fibrosisHUMANIGEN INC·Filed 2017·Application pending·0 cites
Showing the top 50 of 55 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Geoffrey T. Yarranton files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →